Bayer starts new research cooperation in Asia
- Research collaboration with National University of Singapore signed
- Overall investment volume of 10 million Euro
September 30, 2008
“This investment in collaboration agreements with scientific institutions in Asia underscores our commitment to develop novel cancer drugs,” said Prof. Andreas Busch, Head of Global Drug Discovery and member of the Board of Bayer Schering Pharma. “We are looking forward to work together with the experts at NUS and to make use of Singapore’s excellent translational research capabilities and world class research infrastructure to develop and further advance new anti-cancer therapies. We also see this agreement as the start of further research collaborations in Singapore that Bayer will continue to invest in.“
The goal of the joint projects with NUS is to profile oncology drugs in Asian populations, to identify novel biomarkers and to investigate novel tumor models with high relevance for the clinical situation.
Prof. John Wong, Dean of Medical School of National University of Singapore said: “As a comprehensive tertiary institution with significant expertise and interest in translational clinical research, the University looks forward to entering this strategic research collaboration with Bayer that builds on NUS’ existing research capabilities and Bayer Schering Pharma's expertise in drug development. We are hopeful that our joint efforts will translate into discoveries to innovation therapies that will benefit Singaporeans and patients around the world.”
The goal of the joint projects with NUS is to profile oncology drugs in Asian populations, to identify novel biomarkers and to investigate novel tumor models with high relevance for the clinical situation.
Prof. John Wong, Dean of Medical School of National University of Singapore said: “As a comprehensive tertiary institution with significant expertise and interest in translational clinical research, the University looks forward to entering this strategic research collaboration with Bayer that builds on NUS’ existing research capabilities and Bayer Schering Pharma's expertise in drug development. We are hopeful that our joint efforts will translate into discoveries to innovation therapies that will benefit Singaporeans and patients around the world.”
- from Left to Right: Marcus Yim, Managing Director of Bayer (South East Asia)Pte. Ltd. Dr Foo Chuan Kit, Medical Director of South Asia and HK, Bayer Schering Pharma, Dr Karl Ziegelbauer, Vice President of Oncology Research, Bayer Schering Pharma, Associate Professor Manuel Salto-Tellez, Assistant Dean (Research) Yong Loo Lin School of Medicine, National University of Singapore and Dr Richie Soong, Principal Investigator of this project, and Research Associate Professor, Cancer Research Centre of Excellence and Department of Pathology, Yong Loo Lin School of Medicine , National University of Singapore.
- Age-related macular degeneration (AMD)
- Breast cancer
- Central retinal vein occlusion (CRVO)
- Colorectal Cancer (CRC)
- Contraception
- Deficiency Testosterone
- Diabetes
- Diabetic macular edema (DME)
- Endometriosis
- Erectile dysfunction
- Gastrointestinal stromal tumor (GIST)
- Gynecological therapy
- Heart attack
- Heartattack and stroke
- Hemophilia
- High blood pressure
- Infectious diseases
- Liver cancer
- Lung cancer
- Menopausal complaints
- Multiple sclerosis
- Peripheral arterial occlusive disease
- Premenstrual dysphoric disorder (PMDD)
- Prostate cancer
- Pulmonary arterial hypertension
- Renalcell carcinoma
- Stroke
- Thrombosis
- Thyroid Cancer
Page tools
- B/W version
- A | A | A | Font size
